MetLife Investment Management, LLC - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 158 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.

Quarter-by-quarter ownership
MetLife Investment Management, LLC ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2020$47,762
-77.5%
12,569
-69.9%
0.00%
-50.0%
Q4 2019$212,248
+0.7%
41,6990.0%0.00%0.0%
Q3 2019$210,788
-18.1%
41,6990.0%0.00%
-33.3%
Q2 2019$257,282
+71.9%
41,699
+29.2%
0.00%
+50.0%
Q1 2019$149,700
+10.5%
32,2630.0%0.00%0.0%
Q4 2018$135,505
-33.0%
32,2630.0%0.00%0.0%
Q3 2018$202,289
-21.9%
32,2630.0%0.00%
-33.3%
Q2 2018$259,000
+7.5%
32,2630.0%0.00%0.0%
Q1 2018$241,000
+25.5%
32,2630.0%0.00%
+50.0%
Q4 2017$192,00032,2630.00%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q2 2018
NameSharesValueWeighting ↓
Phocas Financial Corp. 1,033,328$6,376,0000.68%
ARDSLEY ADVISORY PARTNERS LP 650,000$4,011,0000.63%
Worth Venture Partners, LLC 138,357$853,0000.47%
RICE HALL JAMES & ASSOCIATES, LLC 2,242,503$13,836,0000.46%
HIGHLAND CAPITAL MANAGEMENT LP 716,880$4,423,0000.26%
FARALLON CAPITAL MANAGEMENT LLC 5,543,386$34,203,0000.22%
Point72 Asset Management, L.P. 5,858,749$36,148,0000.19%
PINNACLE ASSOCIATES LTD 1,298,723$8,013,0000.19%
Fosun International Ltd 472,580$2,750,0000.18%
J. Goldman & Co LP 400,000$2,468,0000.17%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders